Chronic hyperglycemia contributes to diabetic neuropathy, retinopathy, and nephropathy, impacting multiple organ systems and significantly reducing quality of life. Neuropathy manifests as sensory loss, pain, or autonomic dysfunction, requiring early intervention with neuroprotective agents. Retinopathy progresses from mild non-proliferative changes to vision-threatening proliferative stages, necessitating routine ophthalmic evaluations. Nephropathy, a leading cause of end-stage renal disease, is managed through glycemic control, blood pressure regulation, and renoprotective medications like SGLT2 inhibitors. Emerging therapies, including regenerative medicine and targeted molecular interventions, offer hope for slowing or reversing disease progression. Early diagnosis and multidisciplinary management remain key in preventing irreversible damage.
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : Important roles and mechanisms of novel calcium signaling in diabetes-induced vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters?
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : Diabetes reduction (pre-diabetes and type 2) with integrative medicine
F Buck Willis, Belize Bible College, Belize
Title : The menopausal mind: Reframing female senescence as a neuroendocrine disorder with root cause management strategies
Amy Gutman, AdventHealth; Tough Love MD, United States
Title : Bridging the gap: Coaching patients on GLP-1s for sustainable outcomes beyond the prescription
Keith Hersey, Master Your GLP-1, United States